ATyr Pharma Valuation
| ATYR Stock | 0.96 0.01 1.03% |
Today, the firm appears to be overvalued. aTyr Pharma shows a prevailing Real Value of USD0.74 per share. The current price of the firm is USD0.96. Our model approximates the value of aTyr Pharma from analyzing the firm fundamentals such as Return On Equity of -1.03, current valuation of 5.5 M, and Shares Outstanding of 97.99 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ATyr Pharma's valuation include:
Price Book 1.0688 | Enterprise Value | Enterprise Value Ebitda (0.81) | Price Sales 500.3507 | Enterprise Value Revenue 41.6574 |
Overvalued
Today
Please note that ATyr Pharma's price fluctuation is abnormally volatile at this time. Calculation of the real value of aTyr Pharma is based on 3 months time horizon. Increasing ATyr Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ATyr stock is determined by what a typical buyer is willing to pay for full or partial control of aTyr Pharma. Since ATyr Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ATyr Stock. However, ATyr Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.96 | Real 0.74 | Target 4.36 | Hype 0.96 | Naive 1.01 |
The intrinsic value of ATyr Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ATyr Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of aTyr Pharma helps investors to forecast how ATyr stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ATyr Pharma more accurately as focusing exclusively on ATyr Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ATyr Pharma's intrinsic value based on its ongoing forecasts of ATyr Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ATyr Pharma's closest peers.
ATyr Pharma Cash |
|
ATyr Pharma Total Value Analysis
aTyr Pharma is presently anticipated to have valuation of 5.5 M with market capitalization of 95.07 M, debt of 13.28 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ATyr Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.5 M | 95.07 M | 13.28 M |
ATyr Pharma Investor Information
About 60.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.07. Some equities with similar Price to Book (P/B) outperform the market in the long run. aTyr Pharma recorded a loss per share of 0.83. The entity had not issued any dividends in recent years. The firm had 1:14 split on the 1st of July 2019. Based on the key measurements obtained from ATyr Pharma's financial statements, aTyr Pharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.ATyr Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ATyr Pharma has an asset utilization ratio of 0.24 percent. This connotes that the Company is making USD0.002427 for each dollar of assets. An increasing asset utilization means that aTyr Pharma is more efficient with each dollar of assets it utilizes for everyday operations.ATyr Pharma Profitability Analysis
Based on the key profitability measurements obtained from ATyr Pharma's financial statements, aTyr Pharma may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess ATyr Pharma's ability to earn profits and add value for shareholders.Net Loss | First Reported 2013-12-31 | Previous Quarter -19.5 M | Current Value -25.7 M | Quarterly Volatility 4.8 M |
For ATyr Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of aTyr Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ATyr Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ATyr Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ATyr Pharma over time as well as its relative position and ranking within its peers.
ATyr Pharma Earnings per Share Projection vs Actual
By analyzing ATyr Pharma's earnings estimates, investors can diagnose different trends across ATyr Pharma's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for aTyr Pharma is based on EPS before non-recurring items and includes expenses related to employee stock options.ATyr Pharma Ownership Allocation
ATyr Pharma holds a total of 97.99 Million outstanding shares. Over half of ATyr Pharma's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.ATyr Pharma Profitability Analysis
The company reported the previous year's revenue of 235 K. Net Loss for the year was (64.02 M) with loss before overhead, payroll, taxes, and interest of (61.37 M).About ATyr Pharma Valuation
The stock valuation mechanism determines ATyr Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of aTyr Pharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of ATyr Pharma. We calculate exposure to ATyr Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ATyr Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 270.2 K | 283.8 K | |
| Pretax Profit Margin | (313.30) | (297.63) | |
| Operating Profit Margin | (332.35) | (315.73) | |
| Net Loss | (313.30) | (297.64) | |
| Gross Profit Margin | 0.75 | 0.79 |
ATyr Pharma Current Valuation Indicators
ATyr Pharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final ATyr Pharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ATyr Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ATyr Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ATyr Pharma's worth.Additional Tools for ATyr Stock Analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.